Featuring an interview with Dr Alexander E Drilon, including the following topics:

• Overview of targetable biomarkers in lung cancer (0:00)
• Biomarker testing for genomic alterations in lung cancer (5:24)
• Overview of ROS1 alterations in lung cancer (13:44)
• Efficacy data with ROS1 inhibitors for lung cancer (17:02)
• Safety data with ROS1 inhibitors for lung cancer (21:15)
• Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56)
• Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16)
• Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52)

NCPD information and select publications

Featuring an interview with Professor Nicoletta Colombo, including the following topics:

• Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00)
• Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31)
• Definition of platinum ineligibility; importance of platinum-containing chemotherapy for patients with ovarian cancer (14:02)
• Findings from a Phase II trial and the subsequent confirmatory Phase III ROSELLA study (20:25)
• Phase III ROSELLA study: Subgroup analyses, patient-reported outcomes, insights into overall survival data and common adverse events (29:43)
• Considerations for therapeutic selection and sequencing of novel therapies; ongoing and future investigations (38:46)

CME information and select publications

Featuring a slide presentation and related discussion from Professor Nicoletta Colombo, including the following topics:

• Rationale for targeting the glucocorticoid receptor; relacorilant mechanism of action (0:00)
• Key efficacy and safety findings from a Phase II study of relacorilant/nab paclitaxel for platinum-ineligible ovarian cancer (3:09)
• Key findings from the Phase III ROSELLA study (7:06)
• Case: A woman in her early 50s with FIGO Stage IVB platinum-ineligible high-grade serous carcinoma of the fallopian tube enrolls in the Phase III ROSELLA study (15:02)
• Case: A woman in her late 40s with FIGO Stage IIIB platinum-ineligible high-grade serous ovarian carcinoma enrolls in the Phase II BELLA trial (23:42)

CME information and select publications

Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:

• Introduction (0:00)
• First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48)
• Management of HER2-Positive Gastroesophageal Cancer (25:11)
• Neoadjuvant Therapy for Gastroesophageal Cancer (45:13)

Note to listeners: Subsequent to the recording of this symposium, the FDA approved zanidatamab in combination with chemotherapy with and without tislelizumab for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma based on results from the Phase III HERIZON-GEA-01 trial.

CME information and select publications

Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:

• Introduction (0:00)
• First-Line Therapy (2:48)
• Relapsed/Refractory Disease (39:30)

CME information and select publications

Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:

• Introduction (0:00)
• Trials in Progress (1:12)
• Chronic Lymphocytic Leukemia (7:09)
• Diffuse Large B-Cell Lymphoma (32:35)
• Mantle Cell Lymphoma (58:25)
• Follicular Lymphoma (1:14:49)

CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topic:

• Case: A woman in her late 50s with a BRCA1 germline mutation and platinum- and PARP inhibitor-resistant metastatic ovarian cancer with low folate receptor alpha level and HER2 IHC 1+ — Professor Jonathan A Ledermann

CME information and select publications

Featuring a slide presentation and related discussion from Dr Douglas W Sborov, including the following topics:

• Overview of the treatment landscape for early relapsed multiple myeloma (MM) (0:00)
• Belantamab mafodotin (belamaf) mechanism of action and Phase II DREAMM-2 study of belamaf monotherapy in heavily pretreated MM (6:20)
• DREAMM-7 and DREAMM-8 Phase III trials of belamaf combination strategies in patients with MM in the second- and later-line settings (9:20)
• Monitoring for and management of belamaf-related ocular toxicities (12:29)
• Phase I DREAMM-9 trial of belamaf in combination with bortezomib/lenalidomide/dexamethasone (RVd) for transplant-ineligible newly diagnosed MM (16:23)
• Ongoing trials evaluating alternative belamaf dosing; practical considerations and recommendations for the administration of belamaf (19:07)

CME information and select publications

Featuring an interview with Dr Douglas W Sborov, including the following topics:

• DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)
• Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)
• Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)
• Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48)
• Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00)
• Prevention and management of ophthalmic events related to treatment with belamaf (21:27)
• Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49)
• Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27)
• Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53)

CME information and select publications

Featuring perspectives from Dr David W Cescon, including the following topics:

• Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00)
• CNS activity of TROP2-directed antibody-drug conjugates (5:36)
• Autoimmune considerations with immunotherapy (10:09)
• Treatment of oligoprogressive advanced breast cancer (17:31)

CME information and select publications